Critical Contrast: Spruce Biosciences (SPRBD) vs. Its Rivals

Valuation & Earnings

This table compares Spruce Biosciences and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-0.14
Spruce Biosciences Competitors	$162.26 million	-$11.61 million	-407.22

Spruce Biosciences’ competitors have higher revenue, but lower earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Spruce Biosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	N/A	N/A
Spruce Biosciences Competitors	-15,247.28%	32.46%	-33.43%

Insider and Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 24.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 20.8% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Spruce Biosciences has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ competitors have a beta of 0.97, indicating that their average stock price is 3% less volatile than the S&P 500.

Summary

Spruce Biosciences beats its competitors on 5 of the 8 factors compared.